Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 676 - 700 of 14782 in total
Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Approved
Withdrawn
Matched Description: … Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and
Matched Categories: … Alimentary Tract and Metabolism ... magaldrate and antiflatulents ... Aluminum and magnesium containing antacids …
Phthalylsulfathiazole is a broad spectrum antibiotic which is part of the drug class, sulfonamides. It was used as an antibiotic for bowel surgery, and for infections of the colon .
Approved
Matched Description: … It was used as an antibiotic for bowel surgery, and for infections of the colon [A175006]. …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … The FDA and Health Canada advise healthcare providers to inform patients of this risk. ... The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). ... causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … The FDA and Health Canada advise healthcare providers to inform patients of this risk. ... The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). ... causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
Approved
Investigational
Vet approved
Matched Description: … Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Anterior Pituitary Lobe Hormones and Analogues ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Meticrane is a diuretic medication. It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure .
Approved
Matched Description: … It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647 …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated...
Approved
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]
Approved
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... Antiinfectives and Antiseptics for Local Oral Treatment …
Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.
Approved
Investigational
Withdrawn
Matched Description: … Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Approved
Investigational
Matched Description: … It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids...
Approved
Matched Description: … 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296- ... It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab...
Approved
Matched Description: … Food and Drug Administration. ... a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and ... complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and DB09301 , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting...
Approved
Withdrawn
Matched Description: … The active constituents are heparan, dermatan and [DB09301] [T28], and they are isolated from the porcine ... in the United States however it is available in several other countries including European countries and ... Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients...
Approved
Investigational
Matched Description: … the treatment of conditions in which late-stage erythropoiesis is defective, such as beta thalassemia and ... erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins ... Intracellular Signaling Peptides and Proteins …
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of...
Approved
Matched Description: … , disrupting communication between the brain and other parts of the body. ... Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system ... fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically...
Approved
Investigational
Matched Description: … antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and ... Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare ... Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved...
Approved
Matched Description: … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin. It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa. It was developed by Abbott laboratories and in 2009, reviparin presented an orphan...
Approved
Investigational
Matched Description: … [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities. It specifically replicates within...
Approved
Experimental
Investigational
Matched Description: … It specifically replicates within tumor cells and causes lysis. ... laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and ... that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding...
Approved
Matched Description: … It is an anticoagulant and considered an antithrombotic. ... It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. ... Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Approved
Matched Description: … Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia. …
Matched Categories: … quinethazone and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Matched Categories: … Alimentary Tract and Metabolism ... metformin and ertugliflozin ... sitagliptin and ertugliflozin …
Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Inflammation and Infection Detection …
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Description: … in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and ... [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist ... [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... relugolix, estradiol and norethisterone …
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Approved
Investigational
Withdrawn
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Displaying drugs 676 - 700 of 14782 in total